ID   HTOA
AC   CVCL_5457
DR   CLO; CLO_0051442
DR   BioSample; SAMN03472217
DR   CGH-DB; 342-2
DR   CGH-DB; 9351-4
DR   Cosmic; 931366
DR   FANTOM5_SSTAR; 10693-109F9
DR   RCB; RCB0692
DR   Wikidata; Q54896670
RX   PubMed=2429643;
RX   PubMed=2435620;
RX   PubMed=2448191;
RX   PubMed=3593088;
RX   PubMed=9436037;
RX   PubMed=9573483;
RX   PubMed=10457904;
RX   PubMed=11330945;
RX   PubMed=12417041;
RX   PubMed=17671176;
CC   Population: Japanese.
CC   Doubling time: 74.5 hours (Note=At 5th passage), 68.2 hours (Note=At 25th passage), 72 hours (Note=At 50th passage) (PubMed=2435620); 70 hours (PubMed=3593088).
CC   Discontinued: RCB; RCB0692; probable.
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
ST   Source(s): RCB=RCB0692
ST   Amelogenin: X
ST   CSF1PO: 12,13
ST   D13S317: 8,10
ST   D16S539: 9,13
ST   D5S818: 11,13
ST   D7S820: 9,10
ST   TH01: 7
ST   TPOX: 11
ST   vWA: 17
DI   NCIt; C7978; Ovarian serous cystadenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   51Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 19
//
RX   PubMed=2429643; DOI=10.1111/j.1447-0756.1986.tb00192.x;
RA   Ishiwata I., Ishiwata C., Nozawa S., Ishikawa H.;
RT   "CA125 production by gynecologic tumors in vitro and its modulation
RT   induced by dibutyl cyclic adenosine monophosphate.";
RL   Asia Oceania J. Obstet. Gynaecol. 12:285-290(1986).
//
RX   PubMed=2435620; DOI=10.1016/0090-8258(87)90026-6;
RA   Ishiwata I., Ishiwata C., Soma M., Nozawa S., Ishikawa H.;
RT   "Characterization of newly established human ovarian carcinoma cell
RT   line -- special reference of the effects of cis-platinum on cellular
RT   proliferation and release of CA125.";
RL   Gynecol. Oncol. 26:340-354(1987).
//
RX   PubMed=2448191; DOI=10.1016/0090-8258(88)90151-5;
RA   Ishiwata I., Ishiwata C., Soma M., Ono I., Nakaguchi T., Ishikawa H.;
RT   "Tumor angiogenic activity of gynecologic tumor cell lines on the
RT   chorioallantoic membrane.";
RL   Gynecol. Oncol. 29:87-93(1988).
//
RX   PubMed=3593088; DOI=10.1111/j.1447-0756.1987.tb00014.x;
RA   Ishiwata I., Ishiwata C., Nozawa S., Ishikawa H.;
RT   "Cytological properties of human ovarian carcinoma cell lines.";
RL   Asia Oceania J. Obstet. Gynaecol. 13:79-86(1987).
//
RX   PubMed=9436037;
RA   Soma M., Ishiwata I., Ishiwata C., Nakaguchi T., Ono I., Kiguchi K.,
RA   Hashimoto H., Tachibana T., Ishikawa H., Nozawa S.;
RT   "Tissue reconstruction of gynecologic tumor cells in the rotation
RT   culture system.";
RL   Hum. Cell 10:175-181(1997).
//
RX   PubMed=9573483;
RA   Ishiwata I., Tokieda Y., Ishiwata C., Okane N., Iguchi M., Sato K.,
RA   Ishikawa H.;
RT   "Effects of feeder cells (human cancer cell lines) on the development
RT   of mouse embryos by co-culture.";
RL   Hum. Cell 10:237-246(1997).
//
RX   PubMed=10457904;
RA   Ishiwata I., Sudo T., Kiguchi K., Ishikawa H.;
RT   "Tumor angiogenesis factors produced by cancer cells.";
RL   Hum. Cell 12:37-46(1999).
//
RX   PubMed=11330945; DOI=10.1006/gyno.2001.6132;
RA   Watanabe T., Imoto I., Kosugi Y., Ishiwata I., Inoue S., Takayama M.,
RA   Sato A., Inazawa J.;
RT   "A novel amplification at 17q21-23 in ovarian cancer cell lines
RT   detected by comparative genomic hybridization.";
RL   Gynecol. Oncol. 81:172-177(2001).
//
RX   PubMed=12417041; DOI=10.1111/j.1349-7006.2002.tb01213.x; PMCID=PMC5926887;
RA   Watanabe T., Imoto I., Katahira T., Hirasawa A., Ishiwata I., Emi M.,
RA   Takayama M., Sato A., Inazawa J.;
RT   "Differentially regulated genes as putative targets of amplifications
RT   at 20q in ovarian cancers.";
RL   Jpn. J. Cancer Res. 93:1114-1122(2002).
//
RX   PubMed=17671176; DOI=10.1158/0008-5472.CAN-06-4567;
RA   Kikuchi R., Tsuda H., Kanai Y., Kasamatsu T., Sengoku K.,
RA   Hirohashi S., Inazawa J., Imoto I.;
RT   "Promoter hypermethylation contributes to frequent inactivation of a
RT   putative conditional tumor suppressor gene connective tissue growth
RT   factor in ovarian cancer.";
RL   Cancer Res. 67:7095-7105(2007).
//